Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACTISITE vs ACTICLATE CAP
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-t RNA from binding to the A site.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-t RNA binding.
Treatment of periodontal disease (adjunct to scaling and root planing),Topical treatment of infected wounds and skin ulcers
Treatment of infections caused by susceptible bacteria, including respiratory tract infections, urinary tract infections, and acne vulgaris
Topical application of tetracycline hydrochloride 10 mg/g periodontal fiber. Inserted into periodontal pocket and left in place for 10 days.
350 mg orally once daily, increased to 350 mg twice daily if no response after 2 weeks.
Not applicable due to local degradation; systemic half-life is negligible as tetracycline hydrochloride is not absorbed.
Terminal elimination half-life 6-10 hours; prolonged in renal impairment (up to 22 hours in anuria)
Not significantly metabolized; primarily excreted unchanged in urine and feces.
Primarily hepatic; metabolites include 4-epimino derivatives; not significantly metabolized via CYP450.
Primarily eliminated by phagocytic degradation at the application site; minimal systemic absorption, negligible renal or biliary excretion.
Renal (60-70% as unchanged drug), fecal (20-30% as metabolites); minor biliary elimination
Not applicable (no systemic absorption); if systemically present, tetracycline is 50-60% bound to plasma proteins.
90-95% bound to serum proteins, primarily albumin
Not applicable due to lack of systemic absorption; if systemic, tetracycline Vd is 1.3-1.6 L/kg.
0.75 L/kg (50-70 L in adults); distributes well into tissues including bone, teeth, and synovial fluid
Negligible systemic bioavailability (<0.1%) when applied topically; not administered orally or intravenously for periodontal use.
Oral: 90-100% (capsule); food or dairy reduces absorption by up to 50%
Not systemically absorbed; no renal adjustment required.
e GFR 30-59 m L/min: 350 mg once daily; e GFR <30 m L/min: not recommended.
Not systemically absorbed; no hepatic adjustment required.
Child-Pugh A: no adjustment; Child-Pugh B or C: 175 mg once daily.
Safety and efficacy not established in pediatric patients.
Not established for children <12 years; for ≥12 years, same as adult dosing.
No specific dose adjustment; use standard adult dosing with caution for age-related comorbidities.
Initiate at 175 mg once daily; titrate cautiously based on renal function.
None
Photosensitivity: severe sunburn can occur with sun exposure; discontinue if photosensitivity occurs. Tooth development: use during tooth development (last half of pregnancy, infancy, childhood to age 8) may cause permanent tooth discoloration. Bone growth: may retard bone growth in premature infants. Renal toxicity: may cause azotemia, hyperphosphatemia, and acidosis. Avoid in renal impairment.
Photosensitivity,Superinfection with resistant organisms,Use in renal impairment may require dose adjustment,Not recommended in children under 8 years due to permanent tooth discoloration
Photosensitivity, tooth discoloration, bone growth retardation, renal impairment, hepatotoxicity, increased intracranial pressure, superinfection, and use in pregnancy/lactation.
Hypersensitivity to tetracyclines,Severe renal impairment
Hypersensitivity to tetracyclines, pregnancy, breastfeeding, children under 8 years, renal impairment, and concurrent use with oral retinoids.
No direct food interactions. Avoid eating on the treated side to prevent dislodgement of the fiber. Maintain soft diet to minimize trauma. Avoid alcohol-based mouthwashes.
Avoid food and beverages for at least 1 hour before and after administration, as they can reduce the efficacy of activated charcoal. Do not mix with milk or ice cream, as they decrease binding capacity. Administer with water or a non-carbonated, non-alcoholic drink.
FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, tetracycline hydrochloride (active component) caused fetal toxicity (skeletal malformations, reduced fetal weight) at doses 1-2 times the human dose. First trimester: potential for teratogenicity (neural tube defects, cardiovascular anomalies). Second and third trimesters: risk of permanent tooth discoloration (yellow-gray-brown) and enamel hypoplasia in the fetus; also potential for inhibition of fetal bone growth and maternal hepatotoxicity. Use only if potential benefit outweighs risk.
First trimester: Category D; tetracyclines can cause fetal harm including inhibited bone growth and discoloration of teeth (yellow-gray-brown). Second and third trimesters: Known to cause permanent tooth discoloration (enamel hypoplasia) and reversible inhibition of bone growth; use contraindicated after 15 weeks gestation.
Tetracycline is excreted in human milk (M/P ratio approximately 0.6-1.5). Due to potential for serious adverse reactions (tooth discoloration, bone growth inhibition, photosensitivity) in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. Avoid prolonged use during breastfeeding.
Tetracyclines are excreted in breast milk but absorption by the infant is limited due to chelation with milk calcium; M/P ratio for doxycycline is approximately 0.3-0.4. Theoretical risk of tooth staining and bone inhibition, but clinical significance is low with short-term use; caution with prolonged therapy.
No specific dose adjustments for ACTISITE (tetracycline periodontal fiber). Systemic absorption minimal (peak serum concentrations <0.1 mcg/m L). Pregnancy may alter pharmacokinetics of tetracycline (increased volume of distribution, decreased protein binding), but due to local administration, systemic effects are negligible. No dosage adjustment required for the fiber formulation; however, avoid systemic tetracycline use during pregnancy when possible.
No dosage adjustment is typically recommended for doxycycline in pregnancy due to minimal pharmacokinetic changes; however, use is generally avoided in the second and third trimesters. If indicated, standard dosing may be used in the first trimester with caution.
ACTISITE (tetracycline hydrochloride) periodontal fiber is a controlled-release local antibiotic for adjunctive treatment of chronic periodontitis. Insert fiber into periodontal pocket to deliver drug over 10 days. Ensure pocket depth is ≥5mm. Do not use with metallic or synthetic fibers. Fiber must be secured with cyanoacrylate adhesive. Monitor for foreign body sensation, pain, or infection. Removal at 10 days is mandatory to avoid excessive tissue reaction. Not for acute abscesses.
ACTICLATE CAP is a high-dose activated charcoal formulation used for acute poisoning or overdose. Administer within 1 hour of ingestion for optimal efficacy. Do not use in patients with impaired consciousness unless the airway is protected. Monitor for vomiting and ensure rapid administration via nasogastric tube if necessary. Not effective for alcohols, metals, or caustics.
Do not brush or floss the treated area while the fiber is in place.,Avoid chewing hard or sticky foods on the treated side.,You may feel a mild foreign body sensation; report severe pain or swelling.,The fiber must be removed after 10 days; do not leave it longer.,Complete the full course of prescribed oral hygiene and antibiotics if given.
Take ACTICLATE CAP only if directed by a healthcare professional after a poisoning or overdose.,This medication is not for regular use; it is a one-time emergency treatment.,Avoid taking this with food or drinks; take on an empty stomach for best absorption of toxins.,You may experience black stools or vomiting; this is normal.,Seek immediate medical attention if you have trouble swallowing, severe vomiting, or signs of bowel obstruction.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACTISITE vs ACTICLATE CAP, answered by our medical review team.
ACTISITE is a Tetracycline Antibiotic that works by Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-t RNA from binding to the A site.. ACTICLATE CAP is a Tetracycline Antibiotic that works by Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-t RNA binding.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACTISITE and ACTICLATE CAP depend on the specific clinical indication. These are both Tetracycline Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACTISITE is: Topical application of tetracycline hydrochloride 10 mg/g periodontal fiber. Inserted into periodontal pocket and left in place for 10 days.. The standard adult dose of ACTICLATE CAP is: 350 mg orally once daily, increased to 350 mg twice daily if no response after 2 weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACTISITE and ACTICLATE CAP in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACTISITE is classified as Category C. FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, tetracycline hydrochloride (active component) caused fetal toxicity (skeletal malformations, red. ACTICLATE CAP is classified as Category C. First trimester: Category D; tetracyclines can cause fetal harm including inhibited bone growth and discoloration of teeth (yellow-gray-brown). Second and third trimesters: Known t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.